This leads to significant antitumor responses from activated CD8+ and TCF1+ CD8+ T cells, inhibiting tumor growth via intravenous injection instead of conventional s.c. or i.m. administration of the LNP‐neoantigen vaccine. This evidence concerns the gene CD8A and neoplasm.